Abstract:Background: Diabetic peripheral neuropathy (DPN) is the most common complication of diabetes and more than half of the patients with DPN have self-reported symptoms referring to painful diabetic neuropathy (PDN). Nerve growth factor (NGF) is a key factor for the nervous system, but the role of it in the neuropathic pain of diabetic patients is unclear.Objective: This study aimed to investigate the relationship between the dynamic expression of NGF in dorsal horn and dorsal root ganglion (DRG) of diabetic rats and hyperalgesia and allodynia in diabetic neuropathic pain. It also aimed to explore the effects of exogenous mouse NGF (mNGF) on NGF expression in dorsal horn, DRG, and mechanical pain threshold.Study Design: Animal research study.Setting: Experimental research laboratory.Methods: The model of diabetes was established by a single intraperitoneal injection of streptozocin (STZ 55 mg/kg). Firstly, the rats were randomly divided into 2 groups: control group (n = 10) and diabetes group (n = 40). The diabetes group contained 4 subgroups: diabetes week 1 group (DM1, n = 10), diabetes week 2 group (DM2, n = 10), diabetes week 4 group (DM4, n = 10), and diabetes week 8 group (DM8, n = 10). Then, the other rats were randomly divided into 2 groups: control group (n = 10) and treatment group (n = 30). The treatment group contained 3 subgroups: saline group (n = 10), low dose mNGF group (mNGF1, n = 10), and high dose mNGF group (mNGF2, n = 10). Mechanical pain threshold was assessed using Von Frey hairs, before the establishment of the diabetes model and 1, 2, 4, and 8 weeks after the establishment. The NGF expression in dorsal horn and DRG was measured by western blot.Results: The mechanical pain threshold decreased one week after the establishment of the diabetes model, which continued for 8 weeks. The NGF expression in the dorsal horn was reduced 2 weeks after diabetes induction and the decreased NGF expression continued for 4 weeks. However, the NGF expression in DRG was reduced one week after diabetes induction and remained at a low level for 8 weeks. Hyperalgesia occurred when the NGF expression in the DRG decreased and further reduction in the NGF expression in the dorsal horn caused concomitant allodynia. The mechanical pain threshold was significantly elevated 2 weeks after mNGF treatment.Limitations: The course of diabetes should be much longer and there is not a precise analysis of the quantitative relation between the NGF expression in the dorsal horn/DRG and hyperalgesia/allodynia.Conclusion: In diabetic neuropathic pain, the dynamic changes of the NGF expression in dorsal horn and DRG is involved in the development of hyperalgesia and allodynia respectively. Exogenous mNGF may relieve diabetic neuropathic pain by increasing the NGF expression in dorsal horn and DRG.

Role of Spinal Cholecystokinin Octapeptide, Nociceptin/Orphanin FQ, and Hemokinin-1 in Diabetic Allodynia

Decreased Spinal Endomorphin-2 Contributes to Mechanical Allodynia in Streptozotocin-Induced Diabetic Rats

Substance P(1-7) induces antihyperalgesia in diabetic mice through a mechanism involving the naloxone-sensitive sigma receptors

Spinal Astrocytic Activation Contributes to Mechanical Allodynia in a Mouse Model of Type 2 Diabetes.

Identification and quantification of nociceptive Schwann cells in mice with and without Streptozotocin-induced diabetes

Electroacupuncture alleviates diabetes-induced mechanical allodynia and downregulates bradykinin B1 receptor expression in spinal cord dorsal horn

Spinal P2X7R Contributes to Streptozotocin-Induced Mechanical Allodynia in Mice

Extracellular Signal-Regulated Protein Kinase Activation in Spinal Cord Contributes to Pain Hypersensitivity in a Mouse Model of Type 2 Diabetes

Mechanisms Underlying Purinergic P2X3 Receptor-Mediated Mechanical Allodynia Induced in Diabetic Rats

The Different Dynamic Changes of Nerve Growth Factor in the Dorsal Horn and Dorsal Root Ganglion Leads to Hyperalgesia and Allodynia in Diabetic Neuropathic Pain

CXCR4/CX43 Regulate Diabetic Neuropathic Pain Via Intercellular Interactions Between Activated Neurons and Dysfunctional Astrocytes During Late Phase of Diabetes in Rats and the Effects of Antioxidant N-Acetyl-L-Cysteine

The Role of Nav1.7 and Methylglyoxal-Mediated Activation of TRPA1 in Itch and Hypoalgesia in a Murine Model of Type 1 Diabetes.

CXCL13/CXCR5 Signaling Contributes to Diabetes-Induced Tactile Allodynia Via Activating Perk, Pstat3, Pakt Pathways and Pro-Inflammatory Cytokines Production in the Spinal Cord of Male Mice

High-mobility group box 1 contributes to mechanical allodynia and spinal astrocytic activation in a mouse model of type 2 diabetes.

Role of brain derived neurotrophic factor-tyrosinekinase receptor B-potassium-chloride cotransporter pathway in mechanisms of painful diabetic neuropathy in rats

Antiallodynic Effects of Endomorphin-1 and Endomorphin-2 in the Spared Nerve Injury Model of Neuropathic Pain in Mice

Inhibition of Protein Tyrosine Phosphatase 1B in Spinal Cord Dorsal Horn of Rats Attenuated Diabetic Neuropathic Pain

KCNQ2/3/5 Channels in Dorsal Root Ganglion Neurons Can Be Therapeutic Targets of Neuropathic Pain in Diabetic Rats

N-Acetylcysteine Attenuates Hyperalgesia in Rats with Diabetic Neuropathic Pain: Role of Oxidative Stress and Inflammatory Mediators and CXCR4

Inflammatory cytokines in midbrain periaqueductal gray contribute to diabetic induced pain hypersensitivity through phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin signaling pathway

Systemic Demedetomidine Attenuates Mechanical Allodynia Through Extracellular Signal-Regulated Kinase Signaling in Db/db Type 2 Diabetic Mice